PCOS is now PMOS.
The condition formerly known as polycystic ovary syndrome has a new name. Here’s why the terminology is changing and what it means for ultrasound's role in evaluation.
For decades, polycystic ovary syndrome (PCOS) has been one of the most widely recognized hormonal conditions affecting reproductive-aged women. In 2026, an international consensus recommended a new name: polyendocrine metabolic ovarian syndrome (PMOS).
The change is more than a terminology update. It reflects a broader understanding of a complex condition that extends well beyond the ovaries.
Why Is PCOS Being Renamed PMOS?
The term polycystic ovary syndrome has long created a fundamental misconception: that ovarian cysts are central to the condition.
They are not.
Ultrasound may identify multiple small ovarian follicles, not abnormal ovarian cysts. In addition, some patients who meet diagnostic criteria for the condition may not show characteristic ovarian morphology. The emphasis on “polycystic ovaries” therefore placed disproportionate attention on one possible feature of a much broader endocrine and metabolic disorder.
The newly recommended name, polyendocrine metabolic ovarian syndrome (PMOS), is intended to more accurately represent that broader picture:
The change follows a 14-year international effort involving clinicians, researchers, professional organizations, and people with lived experience of the condition. The consensus was published in The Lancet in May 2026.
What Changes With PMOS?
For patients and healthcare providers, the new terminology does not mean that the underlying condition has suddenly changed.
Current diagnostic approaches still consider a combination of clinical and laboratory findings, including irregular or absent ovulation, signs of androgen excess, and characteristic ovarian morphology on ultrasound. The condition can present differently from patient to patient, and not every patient will show every feature.
Similarly, the name change does not immediately introduce new treatment guidelines. Instead, PMOS is intended to encourage a broader view of the condition and its long-term effects.
By moving away from a name centered on ovarian “cysts,” the new terminology places greater emphasis on comprehensive evaluation that considers reproductive, hormonal, and metabolic health together. This may include assessing blood glucose, cholesterol, cardiovascular risk factors, menstrual and ovulatory function, androgen-related symptoms, and fertility concerns, depending on the individual patient.
Because adoption of new medical terminology takes time, clinicians and patients are likely to encounter both PCOS and PMOS in medical records, educational materials, research, and clinical conversations during the transition.
What Does PMOS Mean for Ultrasound?
One key distinction reinforced by the name change is that PMOS is characterized by follicles, not abnormal ovarian cysts. Ultrasound can help assess ovarian morphology, but it is one part of a broader diagnostic evaluation.
Ultrasound can help clinicians evaluate ovarian size, follicle number and distribution, and other pelvic findings while also helping assess alternative causes of a patient’s symptoms.
However, ovarian morphology represents only one part of the diagnostic picture. A patient may have PMOS without demonstrating the characteristic ovarian appearance on ultrasound, reinforcing the need to interpret imaging findings alongside clinical history, signs of androgen excess, menstrual patterns, laboratory testing, and other relevant findings.
The change from PCOS to PMOS therefore does not diminish the value of ultrasound. Instead, it places ultrasound in its proper context: as one component of a broader, multimodal evaluation rather than an imaging diagnosis defined by the presence of “cysts.”
For sonographers, clinicians, and learners, that distinction matters. Recognizing normal ovarian follicles, understanding characteristic ovarian morphology, and accurately evaluating the pelvis can help ensure that imaging findings contribute meaningfully to the overall clinical assessment without overinterpreting ultrasound findings in isolation.
Building OB/GYN Ultrasound Skills With SonoSim
As ultrasound continues to play an important role in evaluating ovarian morphology and other gynecologic findings, proper training is essential for healthcare providers. SonoSim’s OB/GYN ultrasound training covers pelvic and adnexal anatomy, transabdominal and transvaginal scanning techniques, and a range of normal and pathologic findings. Through interactive coursework and virtual scanning practice with real-patient cases, learners can develop image acquisition and interpretation skills across a variety of gynecologic applications.
Explore SonoSim’s OB/GYN ultrasound training to learn more about gynecologic ultrasound education and training solutions.
1. Teede HJ, et al. The global journey to rename polycystic ovary syndrome. The Lancet. May 2026.
2. Endocrine Society. Polyendocrine Metabolic Ovarian Syndrome: New name to improve diagnosis and care of condition affecting 170 million women worldwide. May 12, 2026.
3. Perkes C. UCLA Health. PMOS vs. PCOS: What is the difference? July 14, 2026.
4. MacMillan C. Yale Medicine. PCOS Is Renamed PMOS: What You Need to Know. June 23, 2026.
5. Burrows S. University of Rochester Medicine. PCOS Is Now PMOS: Why This Name Change Matters. May 29, 2026.